-
EP4219556
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4219556
| EP4219556 - HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 26.01.2024 Database last updated on 13.07.2024 | |
| Former | The application has been published Status updated on 30.06.2023 | Most recent event Tooltip | 26.01.2024 | The date on which the examining division becomes responsible, has been established | 26.01.2024 | Request for examination filed | published on 28.02.2024 [2024/09] | 26.01.2024 | Change - designated states | published on 28.02.2024 [2024/09] | Applicant(s) | For all designated states The United States of America as represented by The Secretary Department of Health and Human Services National Institutes of Health Office of Technology Transfer 6011 Executive Boulevard, Suite 325 MSC 7660 Bethesda, MD 20852-7660 / US | [2023/31] | Inventor(s) | 01 /
DIMITROV, Dimiter S. Frederick, 21702 / US | 02 /
CHEN, Weizao Frederick, 21704 / US | 03 /
FRY, Terry J. Bethesda, 20892 / US | 04 /
CHIEN, Christopher Bethesda, 20892 / US | [2023/31] | Representative(s) | Forresters IP LLP Skygarden Erika-Mann-Straße 11 80636 München / DE | [2023/31] | Application number, filing date | 22209293.4 | 21.12.2017 | [2023/31] | Priority number, date | US201662437547P | 21.12.2016 Original published format: US 201662437547 P | [2023/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP4219556 | Date: | 02.08.2023 | Language: | EN | [2023/31] | Type: | A3 Search report | No.: | EP4219556 | Date: | 11.10.2023 | Language: | EN | [2023/41] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 08.09.2023 | Classification | IPC: | C07K16/28, A61K39/00 | [2023/31] | CPC: |
C07K16/2863 (EP,US);
A61K47/6849 (US);
A61K47/6929 (US);
A61P35/00 (EP,US);
A61P35/02 (EP,US);
A61P35/04 (EP,US);
C07K14/7051 (US);
C07K14/70517 (US);
C07K14/70578 (US);
C07K16/468 (US);
G01N33/577 (US);
A61K2039/505 (EP);
C07K2317/21 (US);
C07K2317/31 (US);
C07K2317/52 (EP);
C07K2317/565 (EP,US);
C07K2317/622 (EP,US);
C07K2317/73 (EP);
C07K2317/76 (US);
C07K2319/02 (US);
C07K2319/03 (US);
C07K2319/30 (US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/09] |
| Former [2023/31] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | MENSCHLICHE ANTIKÖRPER SPEZIFISCH FÜR FLT3 UND DEREN VERWENDUNGEN | [2023/31] | English: | HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF | [2023/31] | French: | ANTICORPS HUMAIN SPECIFIQUES POUR FLT3 ET LEUR MODES D'UTILISATION | [2023/31] | Examination procedure | 24.01.2024 | Amendment by applicant (claims and/or description) | 24.01.2024 | Examination requested [2024/09] | 24.01.2024 | Date on which the examining division has become responsible | Parent application(s) Tooltip | EP17835904.8 / EP3559038 | Fees paid | Renewal fee | 30.11.2022 | Renewal fee patent year 03 | 30.11.2022 | Renewal fee patent year 04 | 30.11.2022 | Renewal fee patent year 05 | 30.05.2023 | Renewal fee patent year 06 | 27.12.2023 | Renewal fee patent year 07 | Penalty fee | Additional fee for renewal fee | 31.12.2022 | 06 M06 Fee paid on 30.05.2023 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2009155015 (IMCLONE LLC [US], et al); | [T]WO2017053889 (PREC IMMUNOTHERAPY INC [US]); | [T]WO2017173410 (AMGEN INC [US]); | by applicant | US3896111 | US4137230 | US4151042 | US4235871 | US4248870 | US4256746 | US4260608 | US4265814 | US4294757 | US4307016 | US4308268 | US4308269 | US4309428 | US4313946 | US4315929 | US4317821 | US4322348 | US4331598 | US4361650 | US4362663 | US4364866 | US4371533 | US4424219 | US4450254 | US4501728 | US4689401 | US4837028 | US4892827 | US4902505 | US4957735 | US5004697 | US5019369 | US5055303 | US5061620 | US5079163 | US5188837 | US5208020 | US5254342 | US5268164 | US5271961 | US5413797 | US5506206 | US5512658 | US5514670 | US5534496 | US5602095 | US5608039 | US5635483 | US5663149 | US5712374 | US5714586 | US5739116 | US5767237 | US5767285 | US5780588 | US5821238 | US5854044 | WO9951643 | US6124431 | US6884799 | WO2005052006 | US2006084162 | US7049311 | US7067511 | WO2007016150 | WO2007014743 | WO2007031741 | US7265105 | US2007258986 | WO2009016516 | US2009036431 | WO2009032954 | US7511032 | US7528126 | US7557099 | US2009304710 | US2010047257 | US2010203007 | US2010329981 | WO2011032022 | US2011256157 | WO2011130598 | US2011268655 | WO2012154530 | WO2012170617 | US2013129753 | WO2014052064 | US2015099707 | US19470624375 |